Build the Recurring Revenue Layer From Day One

Becton Dickinson reported fiscal Q2 2026 on May 7 with the BD Interventional segment growing 7.3% reported and 5.3% on a foreign-currency-neutral basis, with mid-single-digit growth across surgery, urology and critical care, and peripheral intervention. The result describes a recurring instrument and consumable economic engine running healthy across an entire focused MedSurg-Interventional portfolio in the same quarter that Intuitive Surgical confirmed roughly 60% of its revenue still flows from instruments and accessories against an 11,395-system installed base. The structural lesson for founders building surgical robotics, advanced interventional, and surgical instrument companies is operational. The durable economics of medtech run through the recurring-revenue layer that lives underneath the platform sale, and the founders who finish in this environment design that recurring layer into the platform from initial product architecture, before the engineering freeze, alongside the regulatory strategy and the indication selection.

If You Are Building a Company in This Environment

The default first-time surgical robotics founder treats the recurring-revenue layer as a downstream output of the platform sale. The system gets engineered first, the company commercializes the cleared system through capital placement, and the instrument and consumable line is whatever the engineering freeze produced as a byproduct of the system design. The internal logic is that the system is the product, the instruments are the accessories, and the recurring-revenue line will follow whatever the installed base eventually produces. The logic is what BD’s Q2 numbers and Intuitive’s installed-base revenue profile both reframe. Roughly 60% of Intuitive’s 2026 revenue runs through the instrument and accessory line, and BD’s most recent quarterly result shows 7.3% growth across a $1.357 billion Interventional portfolio built around recurring access, consumable, and instrument products that run against an installed clinical environment.

The founders who finish in surgical robotics run the operation in the opposite order. They identify the recurring-revenue layer that the cleared system will eventually produce, design the instrument, consumable, and software-service architecture into the platform from initial product architecture, and engineer every system-level decision against the downstream economic implication for the recurring-revenue layer. The work is harder during the platform development phase because the recurring-revenue design competes for time with the visible system progress that drives the next funding round, and the legacy thinking inside the company tends to defer the recurring-revenue work until after the system is cleared. The compensation arrives at the moment the cleared platform reaches commercial scale, when the company that designed the recurring-revenue layer first starts producing the instrument and consumable revenue stream that the BD and Intuitive numbers describe as the durable engine of the medtech category.

The version of recurring-revenue strategy that breaks first-time surgical robotics founders is the one that begins after the system is cleared. The founder discovers in the first commercial cycle that the instruments the system supports do not produce the gross margin the operating plan assumed, that the consumable cadence the system requires does not align with the hospital purchasing pattern, that the design choices that produced the system on the development timeline now produce a recurring-revenue line that is meaningfully thinner than the installed-base economics the strategic-acquirer evaluation assumed. The cost shows up at two specific points. The first is in the second commercial round, when the founder discovers that the unit economics of the cleared platform do not support the operating plan, and the company has to redesign the instrument line or the consumable cadence after the system is already in the installed base. The second is at the strategic conversation, when the buyer evaluates the platform’s installed-base economic profile on a recurring-revenue model that compares unfavorably to the BD and Intuitive operating templates.

The Pattern That Costs Surgical Robotics Founders the Recurring Revenue Layer

The pattern that breaks first-time surgical robotics founders on the recurring-revenue question is treating the instrument and consumable line as a downstream byproduct of system engineering. The pattern produces a predictable timeline. The company raises a Series B against a system development plan and a placeholder instrument-line operating model. The engineering team completes design verification on the cleared system. The commercial team then begins building the instrument and consumable economics against the system that has just frozen, and the line that emerges is the one the system supports rather than the one the installed-base economics actually require. The platform launches with an instrument margin that is thinner than the operating plan assumed, a consumable cadence that runs against the hospital purchasing rhythm rather than with it, and a software-service line that was scoped after the system architecture was already committed.

The cost shows up at two specific points. The first is at the unit-economics conversation in the second commercial round, when the founder discovers that the per-procedure margin does not support the multi-year operating plan and the company has to raise a bridge round to redesign the instrument line against the installed system. The second is at the strategic conversation in the second half of the platform’s commercial life, when the buyer evaluates the recurring-revenue economic profile against the BD and Intuitive operating templates that the integrated commercial story is now priced against. The platforms whose recurring-revenue line was designed after the system was frozen arrive at that conversation with a margin profile that fights the integration story, and the multiples the strategic acquirers will pay for the platform reflect the operational gap.

The companies that finish in this environment do the opposite. They run the recurring-revenue design alongside the system architecture decisions from initial product architecture, fund the instrument and consumable engineering as a Day-1 capital line equivalent in scale to the system engineering and the channel diligence, and protect it during the busy quarters when the operational pressure is on the visible system progress. The work is harder during the run-up to platform clearance, and it produces the cleared system that arrives at first commercial cycle with an instrument margin and a consumable cadence engineered to deliver the recurring-revenue economics that the BD and Intuitive operating templates describe as the durable medtech engine.

What Recurring Revenue Discipline Looks Like at Operating Scale

The companies that win on the recurring-revenue question do specific work that is easy to defer and expensive to skip. They build the instrument and consumable architecture in parallel with the system architecture, identifying every system-level decision that will affect the per-procedure margin, the consumable cadence, and the software-service revenue line. They engage the eventual hospital and ambulatory surgery center customer in instrument-line discovery years before the system clearance gate, with a clear understanding of which instrument designs support which gross-margin structures, which consumable cadences fit which clinical workflows, and which software-service architectures fit which IT and reimbursement environments.

At the operating level, the discipline shows up as a structured recurring-revenue readiness review that runs alongside the system engineering cadence with the same operating cadence and review intensity. The review includes the per-procedure unit economics model, the instrument-life and remanufacturing-pressure model, the consumable cadence by clinical workflow, the software-service revenue architecture by hospital IT environment, and the system-architecture decision impact assessment that maps every engineering decision against its downstream recurring-revenue implication. The output is an instrument and consumable architecture that is ready to commercialize at the moment system clearance lands, that produces the per-procedure margin the operating plan funded, and that fits the BD and Intuitive recurring-revenue operating template at scale.

The Intuitive operating template is the cleanest current example of what the discipline produces over a multi-decade horizon. Roughly 60% of revenue running through instruments and accessories against an 11,395-system installed base, with 23% from system sales and the balance from services, is the recurring-revenue economic profile that the strategic-acquirer evaluation now uses as the comparator for any cleared surgical robotics platform. BD’s Q2 7.3% Interventional growth across surgery, urology and critical care, and peripheral intervention demonstrates the same structural pattern at a different scale and across a different installed environment. The same structure exists in cardiac robotics, in interventional cardiology, in endovascular, in flexible bronchoscopy, and in spine, and the founders who finish are the ones who run the recurring-revenue design with the same discipline BD and Intuitive have institutionalized at operating scale.

The Five Questions for the Surgical Robotics Recurring Revenue Decision

The five-question framework in Founders Who Finish reframes what a credible recurring-revenue strategy actually requires the team to deliver, and where the operational risk concentrates around the instrument and consumable layer.